One-third of patients using oral corticosteroids develop osteoporosis;[9] in addition, 3–5% of patients using a 5-lipoxygenase (ALOX-5) inhibitor develop increases in liver function enzymes.[10] A very small percentage of patients with asthma may be at risk of increased mortality with use of long-acting β-agonists. Here, ALOX5 is linked to asthma.